AbbVie Inc. (ABBV): who owns it and who trades it
As of Nov 16, 2026, ABBV insiders reported 7 open-market sales worth $30.8M and no purchases in the last 12 months, with 31% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jeffrey Ryan Stewart (Vice president), with $11.9M. 9 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling AbbVie
From the latest filingsOverall: more selling than buying. Insiders and Congress mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ABBV
4,190 funds and institutions reported ABBV shares worth $335B at the end of Q2 2026, about 75% of the company. The largest holder is BlackRock, Inc. with 8.5%.
Funds and institutions (13F) 75%Everyone else 25%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 149.49M | 8.46% | $37.6B | -1% |
| Vanguard Capital Management LLC | 115.40M | 6.53% | $29B | +0% |
| State Street Corp | 82.60M | 4.67% | $20.8B | +2% |
| Vanguard Portfolio Management LLC | 48.48M | 2.74% | $12.2B | -2% |
| JPMorgan Chase & Co | 47.86M | 2.71% | $12.2B | – |
| Geode Capital Management, LLC | 47.00M | 2.66% | $11.8B | +1% |
| Morgan Stanley | 38.90M | 2.20% | $9.8B | +2% |
| Capital Research Global Investors | 30.10M | 1.70% | $7.6B | -4% |
| Norges Bank | 25.55M | 1.45% | $6.4B | – |
| Bank of America Corp | 21.24M | 1.20% | $5.3B | -11% |
| FMR LLC (Fidelity) | 20.77M | 1.18% | $5.2B | -5% |
| Northern Trust Corp | 20.56M | 1.16% | $5.2B | -3% |
| Franklin Resources Inc | 19.93M | 1.13% | $5B | +37% |
| Capital World Investors | 19.18M | 1.09% | $4.8B | +21% |
| Goldman Sachs Group Inc | 16.29M | 0.92% | $4.1B | +8% |
| Capital International Investors | 15.64M | 0.89% | $3.9B | +8% |
| T. Rowe Price Associates | 14.75M | 0.83% | $3.7B | +13% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 14.27M | 0.81% | $3.6B | +1% |
| Charles Schwab Investment Management Inc | 12.91M | 0.73% | $3.3B | -0% |
| Bank of New York Mellon Corp | 12.85M | 0.73% | $3.2B | -3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ABBV insiders reported $0 of open-market purchases and $30.8M of sales. 31% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Jeffrey Ryan Stewart | Vice president | Sale | 40,619 | $293.60 | $11.9M | Form 4 |
| Aug 14, 2026 | Nicholas Donoghoe | Vice president | Sale | 32,710 | $250.00 | $8.2M | Form 4 |
| Mar 4, 2026 | David Ryan Purdue | Vice president | Sale | 5,230 | $233.56 | $1.2M | Form 4 |
| Mar 2, 2026 | Perry C Siatis | Vice president | Sale plan | 10,291 | $234.66 | $2.4M | Form 4 |
| Mar 2, 2026 | Perry C Siatis | Vice president | Sale plan | 2,600 | $235.26 | $612K | Form 4 |
| Mar 2, 2026 | Perry C Siatis | Vice president | Sale plan | 5,777 | $233.51 | $1.3M | Form 4 |
| Feb 25, 2026 | Perry C Siatis | Vice president | Sale plan | 22,381 | $230.00 | $5.1M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | – | $11.9M | Nov 9, 2026 |
| Perry C Siatis | EVP, GC AND SECRETARY | – | $9.5M | Mar 2, 2026 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | – | $8.2M | Aug 14, 2026 |
| David Ryan Purdue | SVP, Controller | – | $1.2M | Mar 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ABBV short interest
Low short interest. 0.9% of ABBV shares are sold short: about 1 share in 112. Over the last 12 reports the number of shares short went down 30%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 15.81M ABBV shares were sold short, 0.9% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 4.77M shares, buying them all back would take about 3.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 15.81M | 0.89% | +1% | 4.77M | 3.3 |
| Oct 15, 2026 | 15.58M | 0.88% | -4% | 5.72M | 2.7 |
| Sep 30, 2026 | 16.28M | 0.92% | -16% | 3.94M | 4.1 |
| Sep 15, 2026 | 19.49M | 1.10% | -0% | 4.35M | 4.5 |
| Aug 31, 2026 | 19.51M | 1.10% | +7% | 4.43M | 4.4 |
| Aug 14, 2026 | 18.30M | 1.04% | -19% | 5.12M | 3.6 |
| Jul 31, 2026 | 22.55M | 1.28% | -0% | 5.67M | 4.0 |
| Jul 15, 2026 | 22.63M | 1.28% | +3% | 6.56M | 3.5 |
| Jun 30, 2026 | 21.90M | 1.24% | -7% | 12.55M | 1.8 |
| Jun 15, 2026 | 23.45M | 1.33% | +1% | 5.15M | 4.5 |
| May 29, 2026 | 23.16M | 1.31% | +3% | 5.42M | 4.3 |
| May 15, 2026 | 22.59M | 1.28% | +8% | 5.67M | 4.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded ABBV
Since Nov 17, 2024, 14 members of Congress reported 18 purchases and 17 sales of ABBV. The latest was a sale by Pete Sessions on Sep 14, 2026, reported Sep 18, 2026.
Purchases 18Sales 17
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Pete Sessions (R-TX) | Sale | $15K–$50K | Self | Sep 18, 2026 | Report |
| May 5, 2026 | Josh Gottheimer (D-NJ) | Sale | $1K–$15K | Joint | Jun 3, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $15K–$50K | Self | Jul 21, 2026 | Report |
| Dec 18, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Jan 15, 2026 | Report |
| Dec 8, 2025 | Julia Letlow (R-LA) | Sale | $1K–$15K | Self | Jan 13, 2026 | Report |
| Nov 13, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Dec 11, 2025 | Report |
| Oct 31, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Aug 22, 2025 | John Boozman (R-AR) | Partial sale | $1K–$15K | Joint | Sep 12, 2025 | Report |
| Aug 14, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Sep 11, 2025 | Report |
| Aug 11, 2025 | John Boozman (R-AR) | Partial sale | $1K–$15K | Joint | Sep 12, 2025 | Report |
| Aug 4, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | Aug 15, 2025 | Report |
| Jul 22, 2025 | Lisa C. McClain (R-MI) | Partial sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jul 22, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jul 11, 2025 | Ritchie Torres (D-NY) | Sale | $1K–$15K | Self | Aug 20, 2025 | Report |
| Jun 17, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| May 22, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | Jun 11, 2025 | Report |
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Jun 9, 2025 | Report |
| May 5, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 28, 2025 | Julia Letlow (R-LA) | Purchase | $1K–$15K | Self | Jan 13, 2026 | Report |
| Apr 17, 2025 | Josh Gottheimer (D-NJ) | Sale | $1K–$15K | Joint | May 14, 2025 | Report |
| Apr 17, 2025 | Jefferson Shreve (R-IN) | Sale | $50K–$100K | Self | May 8, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | May 8, 2025 | Report |
| Apr 7, 2025 | Jared Moskowitz (D-FL) | Purchase | $1K–$15K | Self | May 9, 2025 | Report |
| Apr 3, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | May 14, 2025 | Report |
| Apr 3, 2025 | Dwight Evans (D-PA) | Partial sale | $1K–$15K | Self | Apr 17, 2025 | Report |
| Apr 1, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | May 14, 2025 | Report |
| Mar 17, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | Mar 19, 2025 | Report |
| Feb 25, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Mar 27, 2025 | Report |
| Feb 24, 2025 | Jefferson Shreve (R-IN) | Purchase | $50K–$100K | Self | Mar 9, 2025 | Report |
| Jan 24, 2025 | Julia Letlow (R-LA) | Sale | $1K–$15K | Self | Jan 13, 2026 | Report |
| Jan 15, 2025 | Jared Moskowitz (D-FL) | Purchase | $1K–$15K | Child | Feb 10, 2025 | Report |
| Jan 15, 2025 | Jared Moskowitz (D-FL) | Purchase | $1K–$15K | Self | Feb 10, 2025 | Report |
| Dec 6, 2024 | Virginia Foxx (R-NC) | Purchase | $1K–$15K | Self | Jan 6, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
AbbVie company events
AbbVie filed 17 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026LeadershipJennifer L. Davis, a Class II director of AbbVie Inc., notified the Company’s Board of Directors, of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the… Filing
- Oct 30, 2026ResultsReleased financial results. Filing
- Oct 15, 2026LeadershipAbbVie Inc. expanded the size of its Board of Directors from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Filing
- Oct 5, 2026ResultsReleased financial results. Filing
- Sep 3, 2026AnnouncementShared information with investors. Filing
- Aug 18, 2026AnnouncementAbbVie Inc. completed its previously announced underwritten public offering of $500 million of its senior floating rate notes due 2028, $1 billion of its 4.500% senior notes due 2028, $1.25 billion of its 4.650% senior notes due 2030, $1.5 billion of its 4.875% senior notes due 2031, $1.25 billion… Filing
- Aug 5, 2026AnnouncementAbbVie Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein, pursuant to which AbbVie agreed… Filing
- Jul 31, 2026ResultsReleased financial results. Filing
- Jul 6, 2026ResultsReleased financial results. Filing
- Jun 22, 2026AnnouncementShared information with investors. Filing
- May 12, 2026VoteReported shareholder vote results. Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Apr 3, 2026ResultsReleased financial results. Filing
- Mar 4, 2026AnnouncementAbbVie Inc. completed its previously announced underwritten public offering of $750 million of its senior floating rate notes due 2028, $1.5 billion of its 3.775% senior notes due 2028, $1.25 billion of its 4.125% senior notes due 2031, $1.25 billion of its 4.400% senior notes due 2033, $1.5… Filing
- Feb 26, 2026AnnouncementAbbVie Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein, pursuant to which AbbVie agreed… Filing
- Feb 4, 2026ResultsReleased financial results. Filing
- Jan 7, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
How AbbVie makes money
United States brought in 76% of AbbVie's revenue ($46.6B of $61.2B) in 2025. Germany was next, at 3%.
By region, 2025
From AbbVie's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 20, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money
AbbVie financials
Famous investors that hold ABBV
9 of the 50 well-known investors we track reported holding ABBV in their latest 13F filing. The largest position is Ken Fisher's, worth $2.6B.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 10.06M | $2.6B | 0.8% | +6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 609,263 | $159M | 0.1% | -81% |
| Israel Englander · Millennium Management | Q3 2026 | 144,668 | $37.8M | 0.0% | -90% |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 124,770 | $32.6M | 0.6% | -16% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 63,912 | $16.7M | 0.1% | New |
| Tom Russo · Gardner Russo & Quinn | Q3 2026 | 12,410 | $3.2M | 0.0% | No change |
| Bill Nygren · Harris Associates (Oakmark) | Q3 2026 | 2,420 | $633K | 0.0% | No change |
| Lee Ainslie · Maverick Capital | Q3 2026 | 1,018 | $266K | 0.0% | New |
| Jeremy Grantham · GMO | Q3 2026 | 919 | $240K | 0.0% | +4% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about AbbVie Inc. (ABBV) stock
Who owns the most ABBV stock?
The largest reported owner of AbbVie Inc. (ABBV) is BlackRock, Inc., with 8.5% of the company. In total, 4,190 funds and institutions reported holding ABBV at the end of Q2 2026, together about 75% of the shares. See the largest owners.
Are ABBV insiders buying or selling?
In the last 12 months, ABBV insiders reported no open-market purchases and 7 sales worth $30.8M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in ABBV?
As of Oct 30, 2026, 15.81M ABBV shares were sold short, 0.9% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 4.77M shares, buying them all back would take about 3.3 trading days (days to cover). See the history.
Have members of Congress traded ABBV?
Yes. 14 members of Congress reported 18 purchases and 17 sales of ABBV since Nov 17, 2024. The latest was reported on Sep 18, 2026. See the trades.
How does AbbVie make money?
United States brought in 76% of AbbVie's revenue ($46.6B of $61.2B) in 2025. Germany was next, at 3%. See the full split.
Which famous investors hold ABBV?
9 of the 50 well-known investors we track reported ABBV in their latest 13F filing, including Ken Fisher, Ken Griffin, Israel Englander. The largest position is worth $2.6B. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.